KYTX Stock Analysis: Buy, Sell, or Hold?
KYTX - Kyverna Therapeutics, Inc. Common Stock
$8.45
0.02 (0.24%)
▲
5d:
+6.69%
30d:
-2.54%
90d:
+10.6%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When KYTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KYTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KYTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KYTX is currently trading at $8.45, which is considered slightly high relative to its 30-day fair value range of $7.84 to $8.59.
Technical Outlook: Technically, KYTX is showing sideways momentum. The price is approaching resistance at $8.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KYTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $30.40 (+260.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KYTX is showing sideways momentum. The price is approaching resistance at $8.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KYTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $30.40 (+260.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.84 -
$8.59
Company Quality Score
53/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 260.6% below Wall St target ($30.40)
Trading Range Analysis
30-Day Trading Range
$7.84 -
$8.59
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$3.30
(39.1%)
Support & Resistance Levels
Support Level
$7.60
Resistance Level
$8.64
Current Trend
Sideways
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.85
Wall Street Target
$30.40
(+260.6%)
Share & Embed Analysis
Last updated: June 24, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 60 BUY |
